TW202329933A - 咪唑并嗒𠯤ｉｌ—１７抑制劑化合物（一） - Google Patents
咪唑并嗒𠯤ｉｌ—１７抑制劑化合物（一） Download PDFInfo
- Publication number
- TW202329933A TW202329933A TW111136298A TW111136298A TW202329933A TW 202329933 A TW202329933 A TW 202329933A TW 111136298 A TW111136298 A TW 111136298A TW 111136298 A TW111136298 A TW 111136298A TW 202329933 A TW202329933 A TW 202329933A
- Authority
- TW
- Taiwan
- Prior art keywords
- alkyl
- cycloalkyl
- substituted
- compound
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163248563P | 2021-09-27 | 2021-09-27 | |
| US63/248,563 | 2021-09-27 | ||
| US202163273407P | 2021-10-29 | 2021-10-29 | |
| US63/273,407 | 2021-10-29 | ||
| US202263371910P | 2022-08-19 | 2022-08-19 | |
| US63/371,910 | 2022-08-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202329933A true TW202329933A (zh) | 2023-08-01 |
Family
ID=83693127
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW111136298A TW202329933A (zh) | 2021-09-27 | 2022-09-26 | 咪唑并嗒𠯤ｉｌ—１７抑制劑化合物（一） |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US12215111B2 (https=) |
| EP (1) | EP4408529A1 (https=) |
| JP (1) | JP2024536863A (https=) |
| KR (1) | KR20240082371A (https=) |
| AU (1) | AU2022348938A1 (https=) |
| CA (1) | CA3233625A1 (https=) |
| MX (1) | MX2024003770A (https=) |
| TW (1) | TW202329933A (https=) |
| UY (1) | UY39957A (https=) |
| WO (1) | WO2023049886A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240082371A (ko) | 2021-09-27 | 2024-06-10 | 얀센 파마슈티카 엔브이 | 이미다조피리다진 il-17 억제제 화합물 |
| TW202430165A (zh) | 2022-12-02 | 2024-08-01 | 丹麥商理奧藥品公司 | Il-17之小分子調節劑 |
| WO2024138286A1 (en) * | 2022-12-26 | 2024-07-04 | Usynova Pharmaceuticals, Ltd. | Il-17a modulators |
| WO2024163365A1 (en) * | 2023-01-30 | 2024-08-08 | Dice Alpha, Inc. | Benzimidazole and aza-benzimidazole based il-17a modulators and uses thereof |
| CN121311483A (zh) * | 2023-03-28 | 2026-01-09 | 詹森药业有限公司 | 含内酰胺的咪唑并哒嗪il-17抑制剂化合物 |
| WO2025202922A1 (en) * | 2024-03-27 | 2025-10-02 | Janssen Pharmaceutica Nv | Imidazopyridazine il-17 inhibitor compounds |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI752400B (zh) * | 2019-01-07 | 2022-01-11 | 美商美國禮來大藥廠 | Il-17a抑制劑 |
| GB201909190D0 (en) * | 2019-06-26 | 2019-08-07 | Ucb Biopharma Sprl | Therapeutic agents |
| KR20230019507A (ko) | 2020-04-30 | 2023-02-08 | 얀센 파마슈티카 엔.브이. | Il-17의 조절제로서의 이미다조피리다진 |
| WO2023025783A1 (en) | 2021-08-23 | 2023-03-02 | Leo Pharma A/S | Small molecule modulators of il-17 |
| KR20240082371A (ko) | 2021-09-27 | 2024-06-10 | 얀센 파마슈티카 엔브이 | 이미다조피리다진 il-17 억제제 화합물 |
| CN116143777A (zh) | 2021-11-04 | 2023-05-23 | 四川海思科制药有限公司 | 一种可抑制il-17a的杂环化合物及其用途 |
| TW202413363A (zh) | 2021-11-04 | 2024-04-01 | 大陸商西藏海思科製藥有限公司 | 一種可抑制il-17a之雜環化合物及其用途 |
-
2022
- 2022-09-26 KR KR1020247013538A patent/KR20240082371A/ko active Pending
- 2022-09-26 AU AU2022348938A patent/AU2022348938A1/en active Pending
- 2022-09-26 UY UY0001039957A patent/UY39957A/es not_active Application Discontinuation
- 2022-09-26 WO PCT/US2022/077000 patent/WO2023049886A1/en not_active Ceased
- 2022-09-26 CA CA3233625A patent/CA3233625A1/en active Pending
- 2022-09-26 JP JP2024518817A patent/JP2024536863A/ja active Pending
- 2022-09-26 TW TW111136298A patent/TW202329933A/zh unknown
- 2022-09-26 EP EP22790173.3A patent/EP4408529A1/en active Pending
- 2022-09-26 MX MX2024003770A patent/MX2024003770A/es unknown
- 2022-09-26 US US17/935,329 patent/US12215111B2/en active Active
-
2024
- 2024-12-09 US US18/973,307 patent/US20250206744A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US12215111B2 (en) | 2025-02-04 |
| MX2024003770A (es) | 2024-06-19 |
| CA3233625A1 (en) | 2023-03-30 |
| US20230147458A1 (en) | 2023-05-11 |
| UY39957A (es) | 2023-04-14 |
| EP4408529A1 (en) | 2024-08-07 |
| WO2023049886A1 (en) | 2023-03-30 |
| AU2022348938A1 (en) | 2024-05-16 |
| US20250206744A1 (en) | 2025-06-26 |
| JP2024536863A (ja) | 2024-10-08 |
| KR20240082371A (ko) | 2024-06-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW202329933A (zh) | 咪唑并嗒𠯤ｉｌ—１７抑制劑化合物（一） | |
| JP7187729B2 (ja) | Ｒｉｐ１阻害剤化合物並びにそれを製造及び使用するための方法 | |
| JP6862495B2 (ja) | Ｊａｋ及びｐｉ３ｋ阻害剤併用によるｂ細胞悪性腫瘍の処置 | |
| JP7493586B2 (ja) | Ｒｉｐ１阻害化合物ならびにそれを作製および使用するための方法 | |
| AU2013296627C9 (en) | Deuterated ibrutinib | |
| CN115279763A (zh) | Rip1抑制化合物以及制备和使用所述化合物的方法 | |
| TW202330530A (zh) | 咪唑并嗒𠯤ｉｌ－１７抑制劑化合物（二） | |
| CA3181676A1 (en) | Imidazopyridazines as modulators of il-17 | |
| CN121293211A (zh) | 制备咪唑并[1,2-a]吡咯并[2,3-e]吡嗪类化合物及其固态形式的方法 | |
| UA128160C2 (uk) | Сполуки, що інгібують rip1, а також способи їх одержання та застосування | |
| EP4143193B1 (en) | Imidazopyrimidines as modulators of il-17 | |
| JP6837072B2 (ja) | ６，７−ジヒドロ−５Ｈ−ピラゾロ［５，１−ｂ］［１，３］オキサジン−２−カルボキサミド化合物 | |
| JP2025013995A (ja) | Ｒｉｐ１ｋ阻害剤 | |
| TW202540125A (zh) | 雙環雜芳基化合物 | |
| CN118076606A (zh) | 咪唑并哒嗪il-17抑制剂化合物 | |
| CN118317962A (zh) | 咪唑并哒嗪il-17抑制剂化合物 | |
| EA049269B1 (ru) | Соединения ингибиторов il-17 на основе имидазопиридазина | |
| HK40082783A (en) | Rip1 inhibitory compounds and methods for making and using the same |